Vericel (VCEL) Non-Current Assets (2010 - 2026)
Vericel (VCEL) posted Non-Current Assets of $238.1 million for Q2 2026, down 1.42% sequentially from $241.6 million in Q1 2026, and up 3.08% YoY from $231.0 million in Q2 2025.
Vericel (VCEL) Non-Current Assets (2010 - 2026) Analysis & Trends
Vericel has reported Non-Current Assets for 17 years, with the latest figure at $238.1 million in Q2 2026.
- Quarterly Non-Current Assets rose 3.08% year-over-year to $238.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $951.5 million (up 8.4% YoY) and the FY2025 annual result came in at $240.5 million, up 9.36% from the prior year.
- Non-Current Assets slipped to $238.1 million in Q2 2026 per VCEL's latest filing, from $241.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $241.6 million in Q1 2026 and troughed at $81.6 million in Q3 2022.
- A 5-year average of $167.6 million and a median of $173.2 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets decreased 0.97% in 2023, then surged 90.68% in 2024.
- Over 5 years, Non-Current Assets stood at $86.1 million in 2022, then surged by 71.85% to $148.0 million in 2023, then soared by 48.59% to $219.9 million in 2024, then advanced by 9.36% to $240.5 million in 2025, then fell by 1.0% to $238.1 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $238.1 million, $241.6 million, and $240.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 238.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 238.14 Mn |
| Mar 31, 2026 | 241.56 Mn |
| Dec 31, 2025 | 240.53 Mn |
| Sep 30, 2025 | 231.31 Mn |
| Jun 30, 2025 | 231.03 Mn |
| Mar 31, 2025 | 226.95 Mn |
| Dec 31, 2024 | 219.95 Mn |
| Sep 30, 2024 | 199.89 Mn |
| Jun 30, 2024 | 179.45 Mn |
| Mar 31, 2024 | 166.94 Mn |
| Dec 31, 2023 | 148.03 Mn |
| Sep 30, 2023 | 131.91 Mn |
| Jun 30, 2023 | 127.84 Mn |
| Mar 31, 2023 | 87.55 Mn |
| Dec 31, 2022 | 86.14 Mn |
| Sep 30, 2022 | 81.64 Mn |
| Jun 30, 2022 | 89.72 Mn |
| Mar 31, 2022 | 88.41 Mn |
| Dec 31, 2021 | 85.24 Mn |
| Sep 30, 2021 | 79.20 Mn |